Experts estimate that treatment-resistant depression (TRD) impacts about 2.8 million Americans annually, and a groundbreaking ...

Quetiapine (Seroquel) was more clinically effective than lithium as a first-line augmentation option in treatment-resistant ...

A new study has found that antidepressant resistance is more common than was thought: 48% of people with depression have ...

Almost half of patients diagnosed with depression classify as being 'treatment-resistant' as new research suggests that many don't respond to multiple antidepressant options.

Almost half of patients with depression are treatment-resistant and at higher risk for other mental and physical health problems. More options for treatment are urgently needed.

Almost half of people with depression meet criteria for being 'treatment-resistant', found a new study published in the ...

In the sixth episode of The Deep End, listen to what’s next for Jon Nelson and for deep brain stimulation research for depression.

Tiago Costa discusses why ultrasound neuromodulation has significant potential to transform the treatment of depression ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced the completion of recruitment in the COMP005 phase 3 ...

AUSTIN (KXAN)- Experts estimate that treatment-resistant depression (TRD) impacts about 2.8 million Americans annually, and a groundbreaking implantable device may offer new hope. Depression ...

Screening closed for all sites and final participants being scheduled for dosing On track for top-line 6-week primary endpoint results in late Q2 Compass Pathways plc (Nasdaq: CMPS), a ...